Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SCIENTURE Gains FDA Nod for SCN-102, Branded as Arbli (Losartan Suspension)
Details : Arbli (losartan potassium) is an angiotensin II receptor blocker indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.
Product Name : Arbli
Product Type : Hormone
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable